信迪利单抗与白蛋白结合型紫杉醇联合应用于晚期食管癌患者中的效果分析

Effectiveness Analysis of the Combination of Sintilimab and Albumin Bound Paclitaxel in Patients with Advanced Esophageal Cancer

目的分析晚期食管癌患者采用信迪利单抗与白蛋白结合型紫杉醇(Albumin Bound Paclitaxel,nab-PTX)联合治疗的效果。方法随机选取2020年8月-2023年7月滨州市中心医院收治的150例晚期食管癌患者为研究对象,以随机数表法分为两组。对照组(n=75)患者采用nab-PTX联合顺铂化疗治疗,研究组(n=75)患者在对照组治疗基础上联用信迪利单抗治疗。比较两组临床疗效,肿瘤标志物癌胚抗原、细胞角蛋白19片段、鳞状细胞癌抗原水平,以及不良反应。结果研究组客观缓解率(62.67%)、疾病控制率(89.33%)较对照组的42.67%、76.00%高,差异有统计学意义(χ^(2)=6.017、4.653,P均<0.05)。治疗后,与对照组相比,研究组癌胚抗原、细胞角蛋白19片段、鳞状细胞癌抗原水平更低,差异有统计学意义(P均<0.05)。两组胃肠道反应、骨髓抑制、发热、肝功能异常、甲状腺功能减退等不良反应发生率比较,差异无统计学意义(P均>0.05)。结论晚期食管癌患者采用信迪利单抗与nab-PTX联合治疗能够有效提高疾病控制率与客观缓解率,调节肿瘤标志物的表达,且安全性较为理想。

Objective To analyze the effect of combined treatment with sintilimab and albumin bound paclitaxel(nab-PTX)in patients with advanced esophageal cancer.Methods 150 cases of advanced esophageal cancer admitted to Binzhou Central Hospital from August 2020 to July 2023 were randomly selected as the study objects and divided into two groups with reference to the random number table method.The patients in the control group(n=75)were treated with nab-PTX combined with cisplatin chemotherapy,and the patients in the study group(n=75)were treated with a combination of sintilimab in addition to the control group.The clinical efficacy,tumor markers carcinoembryonic antigen,cytokeratin 19 fragment,squamous cell carcinoma antigen levels,and adverse reactions were compared between the two groups.Results The objective remission rate(62.67%)and disease control rate(89.33%)of the study group were higher than those of the control group(42.67%and 76.00%),and the differences were statistically significant(χ^(2)=6.017,4.653,both P<0.05).After treatment,compared with the control group,the study group had lower levels of car-cinoembryonic antigen,cytokeratin 19 fragment,and squamous cell carcinoma antigen,and the differences were statis-tically significant(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions such as gastrointestinal reactions,bone marrow suppression,fever,liver function abnormality and hypothyroidism be-tween the two groups(all P>0.05).Conclusion The combined treatment of advanced esophageal cancer patients with sintilimab and nab-PTX can effectively improve the disease control rate and objective remission rate,regulate the expression of tumor markers,with ideal safety.